Antibodies
25 January 2025
ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting23 January 2025
Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure22 January 2025
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas22 January 2025
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer22 January 2025
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 202520 January 2025
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe20 January 2025
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B0220 January 2025
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama18 January 2025
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer15 January 2025
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference15 January 2025
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports